Galaxy Therapeutics is a MedTech startup developing a proprietary intrasaccular device to treat intracranial aneurysms. Based in the United States with sites around the world, the company is bringing a disruptive alternative to a market that has seen little change in over two decades.

Sergi López García, Global Clinical Marketing and Commercial Director at Galaxy Therapeutics, leads the clinical and commercial strategy and serves as the primary point of contact for the study.

At the time of this study, Galaxy Therapeutics was in a pre-commercialization phase, actively navigating regulatory pathways. Like many MedTech startups, Galaxy Therapeutics faced a familiar tension: while regulatory trials are essential, they are also highly constrained.

To fill this gap, Galaxy launched a real-world study to complement its regulatory research. The study included participating sites across multiple geographies, including the US, Colombia, New Zealand, Spain, and Pakistan.

However, managing data collection across these regions introduced new challenges:

• Technology usage varied widely across hospitals and regions, with differing levels of digital maturity
• Manual processes like handwritten documentation and physical binders were difficult to track and manage remotely
• Galaxy operates as a lean startup without a large, dedicated clinical operations team

“I’m based in Barcelona, the company is based in the United States, and we don’t have an army of people in the clinical department,” Sergi noted. “So anything that wasn’t easy to manage remotely would have been a challenge.”

To navigate these trials, Sergi and his team knew they needed a tool that could coordinate data collection across the globe without adding significant administrative or cost burden. 

Galaxy Therapeutics partnered with ResearchManager to serve as its Electronic Data Capture (EDC) platform. The goal was straightforward: enable global participation, simplify data collection, and remain compliant, without putting pressure on the team or the budget.

Here’s what made ResearchManager the right tool for Galaxy Therapeutics’ study:

While some hospitals in the study were already using digital tools, others had relied primarily on paper-based data collection. As a result, Galaxy needed a system that could support consistent data access across sites with very different levels of digital maturity.

ResearchManager’s EDC enabled sites to enter patient data directly into a centralized online database. This allowed Sergi and his team to access study data remotely, regardless of location, eliminating the need to manage physical documentation across international sites.

“Before, it was paper and pen, binders, scanning documents,” Sergi said. “That’s difficult to track, especially when you’re not living there.”

 

Introducing a new system can often meet resistance, especially in hospital settings, where staff are accustomed to established platforms and workflows. 

According to Sergi, ResearchManager’s intuitive interface helped teams get up to speed quickly. With minimal setup, most users became comfortable with the platform in a short period of time.

“It’s not a difficult tool,” Sergi said. “It’s a nice platform.”

When questions did arise, particularly during the onboarding process, support was easy to access.

“We raised a ticket, they contacted us by email, we scheduled an online meeting, shared the screen, and went through it,” Sergi said.

Over time, that support enabled greater independence. Sergi now manages form updates and user access directly within the platform.

“Now I’m pretty independent,” he said. “I can modify the forms as much as I want.”

 

Because the study involved patient data, privacy and regulatory compliance were non-negotiable selection criteria.

“That was part of the discussion and selection criteria,” Sergi explained. “We needed to make sure they were compliant with European and global regulations.”

Just as importantly, the platform aligned with Galaxy’s needs and budget.

“For the type of studies we’re running, it’s as simple as we need, as useful as we need—and for a pretty decent price,” Sergi said. “It ticks all the boxes”

 

By using ResearchManager, Galaxy Therapeutics was able to operate a truly global real-world registry without expanding headcount or limiting participation to regions where the company had a physical presence.

“Using a tool like this has allowed us to include patients from New Zealand, Colombia, Barcelona, Pakistan,” Sergi shared. “Otherwise, unless we had people located in each geography, we couldn’t have done it”

The platform reduced reliance on manual workflows, eliminated redundant data handling, and allowed Galaxy to move quickly and independently as the study evolved.

“For our reality — the world we live in and the world we work in — it’s a spot-on solution,” Sergi concluded.

To learn more about how ResearchManager can support your clinical trials, book a free demo with our team.